Tao Xie to Supranuclear Palsy, Progressive
This is a "connection" page, showing publications Tao Xie has written about Supranuclear Palsy, Progressive.
Connection Strength
3.612
-
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
Score: 0.888
-
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci. 2021 Feb 15; 421:117293.
Score: 0.773
-
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
Score: 0.329
-
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
Score: 0.314
-
Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
Score: 0.289
-
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
Score: 0.245
-
Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
Score: 0.215
-
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
Score: 0.211
-
Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
Score: 0.176
-
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
Score: 0.173